21 June 2022

Androgen receptor (AR-V7 splice variant-specific) antibodies

Check out GeneTex’s recombinant monoclonal androgen receptor (AR-V7 splice variant-specific) antibodies.


In advanced prostate cancer, androgen receptor splice variant 7 (AR-V7) is the most abundant androgen receptor mRNA splice variant and generates a protein lacking the ligand-binding domain with resultant ligand-independent, constitutive transcriptional activity. Mechanistic and clinical studies have shown that AR-V7 is not only a biomarker for resistance to second-generation androgen receptor signaling inhibitors, but also functions in driving that phenotype (Ref. 1, 2). This makes AR-V7 a crucial marker for therapeutic decision-making by directing clinicians to use taxane therapy in cases of high-risk prostate cancer.

Androgen receptor antibodies by GeneTex

GeneTex’s androgen receptor (AR-V7 splice variant) antibodies ([HL1028] (GTX635842) and [HL1240] (GTX636639)) are recombinant rabbit antibodies whose specificity for the AR-V7 mutant was confirmed using extracts from high-/low-expression cell lines (see the data images below). Also offered is a recombinant antibody detecting the full-length androgen receptor (see below; [HL1049] (GTX636021)).

References

  1. Zhu Y, Dalrymple SL, Coleman I, et al. Role of androgen receptor splice variant-7 (Ar-v7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. 2020;39(45):6935-6949.
  2. Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE. Androgen receptor splice variant, ar-v7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer. 2020;18(1):1-10.

GeneTex releases high quality recombinant antibodies

To learn more about GeneTex’s expanding catalog of recombinant antibodies, please go to www.genetex.com.

Androgen receptor (AR-V7 splice variant-specific) antibodies

Related articles

Newsletter for researchers

We gladly support you by keeping you updated on our latest products and the developments around our services.

we Connect you
Need help? Contact our technical support
Contact